News | Prostate Cancer | September 19, 2018

Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence

Promising early results of AI applied to micro-ultrasound for targeted biopsies could improve the speed at which prostate cancer is detected

Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence

September 19, 2018 — Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to improve the way prostate cancer is visualized and detected. Cambridge Consultants is applying deep learning, also known as artificial intelligence (AI), to high-resolution micro-ultrasound imaging to identify potential suspicious regions of tissue and inform urologists who may want to consider this additional data in their biopsy protocol. Early results show real promise, according to both companies.

Prostate cancer is the second most common cause of cancer death in men in both the U.S. and the U.K. There is an urgent need for improved accuracy in the detection and diagnosis of aggressive prostate cancers. The current standard-of-care ultrasound, which guides prostatic needle biopsies that help to diagnose prostate cancer, yields a 30 percent false negative rate as the resolution of the ultrasound systems is insufficient to differentiate suspicious regions. As such, the prostate biopsies are usually delivered in a systematic, “blind” pattern.1

The ExactVu micro-ultrasound platform allows urologists to harness “micro”-ultrasound’s near microscopic resolution in order to visualize suspicious regions and actually target their biopsies to those regions. Operating at 29 MHz, the micro-ultrasound provides a 300 percent improvement in resolution over conventional ultrasound.

With Cambridge Consultants’ AI tools being able to interrogate the full ultrasound data set when correlated to pathology, the analysis should deliver improved accuracy and better characterization of suspicious regions. The machine learning approach being applied is faster and less computationally intensive than traditional statistical approaches; this may ultimately form the backbone of a commercially-viable software application. Early results from proof of concept testing show significant promise, even with relatively limited data sets, according to the company.

The current work on prostate cancer is the latest output from Cambridge Consultants’ Digital Greenhouse2, an experimental environment where data scientists and engineers explore and develop machine learning and deep learning techniques. The Digital Greenhouse aims to ensure that deep learning is potent beyond the huge online datasets that have powered advances to date. Recent work has focused on applying deep learning in areas where massive datasets are unavailable. In the case of its work on prostate cancer, data was available for hundreds of patients.

For more information: www.exactimaging.com, www.cambridgeconsultants.com

 

References

1. https://www.ncbi.nlm.nih.gov/pubmed/23452046#

2. http://digitalgreenhouse.ai/

Related Content

Warm Springs Health & Wellness Center Implements Digisonics Solution for OB Ultrasound
News | Ultrasound Women's Health | June 17, 2019
Warm Springs Health & Wellness Center in Warm Springs, Ore., has selected the Digisonics OB PACS (picture archiving...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
Sectra Providing Centralized Regional Solution for Digital Pathology in the U.K.
News | Digital Pathology | June 14, 2019
Sectra has signed a five-year contract with North Tees and Hartlepool National Health System (NHS) Foundation Trust for...
M*Modal and Community Health Network Partner on AI-powered Clinical Documentation
News | PACS Accessories | June 13, 2019
M*Modal announced that the company and Community Health Network (CHNw) are collaborating to transform the patient-...
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
Konica Minolta Healthcare Announces Autologous Biologics Workshop in Partnership With EmCyte Corp.
News | Ultrasound Imaging | June 12, 2019
Konica Minolta Healthcare announced a new autologous biologics workshop in partnership with EmCyte Corp. The workshop...
The Current Direction of Healthcare Reform Explained by CMS Administrator Seema Verma
News | Radiology Business | June 11, 2019
June 11, 2019 — Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma addressed the American Med
Aidoc Earns FDA Approval for AI for C-spine Fractures
Technology | Artificial Intelligence | June 11, 2019
Radiology artificial intelligence (AI) provider Aidoc announced the U.S. Food and Drug Administration (FDA) has cleared...
Medivis SurgicalAR Gets FDA Clearance
Technology | Virtual and Augmented Reality | June 10, 2019
Medivis announced that its augmented reality (AR) technology platform for surgical applications, SurgicalAR, has...
Glassbeam Announces New Clinsights Application Suite for Healthcare Provider Market
Technology | Analytics Software | June 10, 2019
Glassbeam launched Clinsights, a new revitalized application suite powered by artificial intelligence/machine learning...